July 10, 2017
Phenex AG announces milestone payment from Janssen for the entry of RORγt inhibitor into Phase I
Phenex drug discovery has now resulted in two clinical stage programs this year through research…
February 23, 2016
Phenex Announces Milestone Payment from Gilead as FXR drug candidate GS-9674 Enters Phase 1 Study
Ludwigshafen, Germany, April 23, 2016 "The revenues from this milestone further secure our strong cash…
December 17, 2015
Phenex AG reaches milestone in collaboration with Janssen
Milestone payment results in further profitability in fiscal year 2015, continuing the trend from 2014…
December 17, 2012
Phenex enters into a Research Collaboration and License Agreement with Janssen for Autoimmune and Chronic Inflammatory Disorders
Phenex will receive an upfront payment and is eligible to receive development-related milestones. Ludwigshafen, Germany,…
October 31, 2012
Phenex reports successful completion of Phase I Studies with FXR-Agonist Px-102 and publishes research progress in two independent papers
On the back of the good scientific news, Phenex raises 5 Mio Euro in its…
September 15, 2011
Phenex initiates Phase I first-in-man study with its clinical development candidate Px-102
The FXR agonist Px-102 might open new avenues for the treatment of Non-Alcoholic Steatohepatitis (NASH)…
Contact
Waldhofer Str. 104
69123 Heidelberg, Germany
Phone: +49 6221 65282-0
Fax: +49 6221 65282-10
Dr. Claus Kremoser
Thomas Hoffmann
mailto: info@phenex-pharma.com
About Phenex Pharmaceuticals AG
Phenex is a privately held drug discovery and development company headquartered in Ludwigshafen with a research site in Heidelberg. The biopharmaceutical company can now build on nineteen years of expertise in exploring and defining innovative, potent and selective new drug candidates from small molecules. Phenex´s R&D activities are centered around diseases of liver such as NASH and cancer.
